"ASH is dedicated to supporting the next generation of hematology physicians and scientists, especially in this time of funding uncertainty," Belinda R. Avalos, MD, ASH president, says. "It is crucial that we invest in emerging hematologists who combine cutting-edge science with compassionate care to diagnose, treat, and advocate for patients with complex, life-threatening blood disorders."

Brenner's work carries profound implications for pediatric care, where pathologic venous thromboembolism affects one of every 100 hospitalized children in the United States each year. Her research investigates how inflammation increases the risk of blood clot formation and examines the crucial role of platelets in these events, particularly given that inflammatory diseases significantly increase the risk of hospital-associated blood clots in children.

"We are witnessing how inflammation fundamentally alters the way blood clots form," Brenner says. "By understanding these mechanisms, particularly the changes we see in platelet glycosylation during thrombotic events, we hope to identify new approaches for preventing and treating these devastating complications in our most vulnerable patients."

The collaborative nature of this research exemplifies Versiti's commitment to nurturing emerging physician-scientists. Working alongside Brian Branchford, MD, and Karin Hoffmeister, MD, Brenner represents the next generation of researchers translating laboratory discoveries into life-saving treatments.

"I am honored to be awarded the 2025 RTAF from ASH," said Dr. Brenner. "ASH is an amazing organization, and this award not only supports my research but also demonstrates how Versiti empowers fellows to pursue their scientific aspirations while contributing to our collective understanding of blood disorders."

The research may ultimately lead to novel therapeutic approaches for preventing platelet-driven blood clots in inflammatory conditions and could help identify glycosylation patterns that predict thrombotic events, opening new pathways for treatment and prevention strategies.